-ADRENOCEPTOR ANTAGONISTS

Slides:



Advertisements
Similar presentations
Jara – Medrano (“Jarano”). * Indications: acute bronchospasm, severe bronchospasm, acute severe asthma * Pharmacokinetics: * Route: Inhaled, oral * Absorption:
Advertisements

Adrenoceptor antagonist drugs Department of pharmacology Zhu ling ( 朱玲 )
Bianca Moses Fall LOL β-Blockers For the treatment of the symptoms of attack by ostriches…and other ailments; including those of the cardio-pulmonary.
Assoc. Prof. Ivan Lambev ANTIADRENERGIC DRUGS (Sympatholytics, Adrenolytics)
Pharmacology II The Autonomic Nervous System Adrenergic antagonists
Beta-Adrenergic Blockers  Types of adrenoceptors Alpha-1  Vasoconstriction  Increased peripheral resistance  Increased blood pressure Alpha-2  Inhibition.
Alpha-Receptor Antagonist Drugs
ALPHA BLOCKERS Alpha receptors have been further subdivided into alpha1 and alpha2 receptors. Alpha -1 receptors – Upon stimulation, leads to increased.
Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc. Chapter 18 Adrenergic Antagonists.
Adrenergic Blockers Asmah Nasser, M.D..
Joseph De Soto MD, PhD, FAIC. Overview The adrenergic antagonist bind adrenoreceptors either reversibly or irreversibly preventing or reducing activation.
Heart Failure. How do  -blockers work? Mechanism for How It Works ・ Beta-blockers "block" the effects of adrenaline on your body's beta-receptors. This.
Adrenoceptor Blockers
ADRENERGIC ANTAGONITS
Head Lines Etiology Risk factors Mechanism Complications Treatment.
Adrenergic antagonist sympatholytic
1 β- Adrenoceptor Antagonist Drugs. 2 The β -receptor–blocking drugs differ in their relative affinities for β 1 and β 2 receptors. Some have a higher.
Adrenergic Antagonist (Sympatholytics)
Table 1. Biological Responses Mediated by Adrenergic Receptors in the Human Heart Biological ResponseAdrenergic Receptor Mediation Cardiac myocyte growthß.
OBJECTIVES At the end of lectures the students should Describe the different classes of drugs used for treatment of acute & chronic heart failure.
1 Drug Treatment of heart failure. Prof. Azza El-Medani Prof. Abdulrahman Almotrefi.
SYMPATHOMIMETICS Classification: A- According to the source:
Beta Blockers.
ANTI-ADRENERGIC DRUGS
HuBio 543 September 27, 2007 Neil M. Nathanson K-536A, HSB
Adrenolytics. Adrenoceptor Blockers Adrenolytics Adrenergic Neuron Blockers Sympatholytics Alpha & beta- adrenergic receptor blockers.
1 Drug Therapy of heart failure. Prof. Azza El-Medani Prof. Abdulrahman Almotrefi.
Bipyridines :(Amrinone,Milrinone ) only available in parenteral form. Half-life 3-6hrs. Excreted in urine.
Adrenergic Receptor Antagonists Excessive sympathetic activity is characteristic of a number of pathological states including: Hypertension Angina pectoris.
Synthesis & Release of Neurotransmitters
AUTONOMICS MA. JANETTH B. SERRANO, M.D. DPBA. Site and Mode of Action: Site and Mode of Action: 1. Direct Acting –Epinephrine- Dobutamine –Phenylephrine-
Alpha & beta- adrenergic receptor blockers Adrenoceptor Blockers Adrenolytics Adrenergic Neuron Blockers Sympatholytics  Form False Transmitters  Deplete.
Adrenoceptor antagonist drugs Pawitra Pulbutr M.Sc. In Pharm (Pharmacology) Pawitra Pulbutr M.Sc. In Pharm (Pharmacology)
BETA ADRENOCEPTOR BLOCKERS. OCH 2 CH CH 2 NHCH CH 3 OH CH 2 CH CH 2 NHCH OH CH 3 CH 3 OCHCH 2 PROPRANOLOL METOPROLOL.
Adrenergic Antagonists (Sympatholytics)
Fate of Local Anesthetics
PHARMACOLOGY OF ANS part 3 General Pharmacology M212
Alpha Adrenoceptor Antagonists Beta Adrenoceptor Antagonists Ganglion-Blocking Drugs 1.
Sympathetic Nervous System.
Adrenergic Antagonists
 - Adrenoceptors blockers Prof. Hanan Hagar Pharmacology Unit College of Medicine.
SYMPATHOLYTIC AGENTS Beta Receptor Blockers. BETA-ADRENERGIC RECEPTOR BLOCKERS  Widely used clinically for a variety of conditions ; mainly CVS  Dichloro-isoproterenol.
* QUINIDINE  Quinidine has pronounced cardiac anti muscarinic effects. It is absorbed orally. It undergoes extensive metabolism by the hepatic cytochrome.
PHARMACOLOGY OFADRENERGICS
Adrenergic Receptor Antagonists These are drugs which antagonize α or β or both α and β adrenergic receptors Adrenergic neurone blocking agents (Sympatholytic)
1 ADRENERGIC ANTAGONITS. 2 ADRENERGIC BLOCKERS ALPHA BLOCKERS Alpha 1 Blockers Nonselective Alpha Blockers Doxazosin Phenoxybenzamine Prazosin Phentolamine.
Sympatholytic & adrenergic blockers -receptor Antagonists
Adrenergic Antagonists
Alpha & beta- adrenergic receptor blockers Adrenoceptor Blockers Adrenolytics Adrenergic Neuron Blockers Sympatholytics  Form False Transmitters  Deplete.
Investigation of the effects of ß-blockers on CVS
PHARMACOLOGY OFADRENERGICS
Sympatholytic & adrenergic blockers -receptor Antagonists
β-adrenergic antagonists
- Adrenoceptors blockers
Adrenoceptor Antagonist Drugs
β – ADRENERGIC BLOCKERS
Cholinergic Antagonist
ANTI HYPERTENSIVE DRUGS
ANTI HYPERTENSIVE DRUGS
Beta-adrenergic blocking agents
Effect of β-adrenergic Blockers on the Arterial Blood Pressure
Anti hypertensive Drugs
Beta blockers and anesthesia
Adrenergic agonists and antagonists
- Adrenoceptors blockers
Adrenergic Antagonist
Adrenergic Antagonists
Chaper 20 Adrenoceptor Antagonists
BETABLOCKERS THIRUMURUGAN E MSC CVT. SYMPATHETIC NERVOUS SYSTEM  FIGHT  FEAR  FLIGHT.
Presentation transcript:

-ADRENOCEPTOR ANTAGONISTS ( -BLOCKERS )

CLASSIFICATION I. ACCORDING TO SELECTIVITY A) NON-SELECTIVE (1, 2) BLOCKERS 1. PURE BLOCKES v SOTALOL v TIMOLOL v NADOLOL 2. WITH MEMBRANE STABILIZING ACTIVITY (MSA) v PROPANOLOL 3. WITH INTRINSIC SYMPATHETIC ACTIVITY (ISA) v PENBUTOLOL v CARTEOLOL 4. WITH ISA & MSA v OXPRENOLOL v ALPRENOLOL v PINDOLOL (MSA )

B) CARDIOSELECTIVE (1) BLOCKERES 1. PURE BLOCKERS v ATENOLOL v BISOPROLOL 2. WITH MSA v METOPROLOL v TOLAMOLOL v BETAXOLOL 3. WITH ISA v PRACTALOL 4. WITH ISA & MSA v ACEBUTALOL C) BOTH  &  BLOCKERS v LABETALOL v CARVEDILOL D) 1 BLOCKER WITH PARTIAL 2 AGONIST ACTIVITY v CELIPROLOL E) 2 selective blocker Butoxamine, used only in research.

CLASSIFICATION II. ACCORDING TO SOLUBILITY LIPID SOLUBLE PROPRANOLOL TIMOLOL METOPROLOL WATER SOLUBLE NADOLOL ATENOLOL

CLASSIFICATION III. ACCORDING TO DURATION OF ACTION ULTRA SHORT ACTING ESMOLOL t ½ 9min INTERMEDIATE ACTING PROPRANOLOL 3-5 hours PINDOLOL 3-4 hours METOPROLOL 3-4 hours LONG ACTING NADOLOL 10-20 hours ATENOLOL 05-08 hours BISOPROLOL

PHARMACOKINETICS

Absorption: well absorbed orally, peak concentration 1-3 hrs Sustained release preparations are available Bioavailability: Propranolol extensive hepatic (first pass metabolism) Rapidly distributed and have large volume of distribution. Can cross blood brain barrier

Nadolol is excreted unchanged in urine and has longest half life of 24 hrs.

EFFECT OF BINDING OF ADRENALINE TO  RECEPTORS. -Receptor are G Protein Mediated Binding Adrenaline to  Receptors (Extracellular) Stimulation of Adenyl cyclase (intracellular) Increase Conversion of ATP to cAMP Stimulation of Protein Kinase C. Phosphorylation of Enzymes (Enzyme-PO4) Response

PHARMACOLOGICAL ACTIONS 1.      CVS

Suppression of renin release and effects in the central nervous system. Prominent effect on heart Negative inotropic and chronotropic effects. In vascular system, β2 mediated vasodilatation

3. Eye (reduce aqueous humor production) 2.  Respiratory System (increase in airway resistance) 3.  Eye (reduce aqueous humor production) 4.   Metabolism (increase VLDL and decrease HDL 5.   Intrinsic Sympathomimetic Activity (ISA) Precipitation of asthma, excessive bradycardia is prevented 6. Membrane stabilizing Activity (MSA) Local anesthetic action (Na+ channel blockade)

THERAPEUTIC USES ANTI-HYPERTENSIVE ANTI-ANGINAL (reduce the frequency of anginal episode) ANTI-ARRHYTHMIC Prophylaxis after myocardial infarction, Treatment of other Cardiac Arrhythmias, Supraventricular and ventricular arrhythmias. Sotalol Metoprolol Timolol Propranolol Esmolol Acebutolol

Slowing of ventricular ejection and decrease outflow resistance. MYOCARDIAL INFARACTION (MI) (prolong survival) HYPERTROPHIC SUBAORTIC STENOSIS HYPERTROPHIC CARDIOMYOPATHY: Propranolol Slowing of ventricular ejection and decrease outflow resistance.

THYRO TOXICOSIS, Thyroid storm: Inhibition of peripheral conversion of thyroxine to triiodothyronine GLAUCOMA: TIMOLOL BETAXOLOL Reduce production of aqueous humor by ciliary body

MIGRAINE (frequency and intensity of migraine attacks) PHEOCHROMOCYTOMA: LABETALOL TREATMENT OF CHRONIC (NOT ACUTE) CCF: LABETALOL CARVEDILOL

FAMILAL TREMORS, OTHER TYPES OF TREMORS (sympathetic activity may enhance skeletal muscle tremor)

ANXIETY Alcohol WITHDRAWAL SYNDROME (symptomatic treatment) PORTAL HYPERTENSION ACUTE PANIC SYMPTOMS – stage fright, viva-voce examination, public appearance etc. (PROPAYLACTIC USE)

ADVERSE EFFECTS 1. CNS (bad dreams, lassitude, depression). 2. CVS (Congestive Cardiac failure, Bradycardia, Atrioventricular blockade). 3. METABOLIC EFFECTS HYPOGLYCEMIA – exercise induced, insulin induced. Slow recovery from hypoglycemia and masking the manifestations of sympathetic activity due to exercise / insulin induced hypoglycemia in diabetic patients, resulting in loss of warning signal and the patient may land into hypoglycemic coma.

4. RESPIRATORY EFFECTS Bronchoconstriction Worsening of preexisting asthma

5. COLDNESS OF EXTREMITIES 6. FATIGUE 7. Aggravation of diabetes mellitus, hyperlipidemic states, peripheral vascular spastic diseases by the use of Non selective beta blockers. 8. ADVERSE EFFECTS ON SUDDEN WITHDRAWAL (up regulation of receptors)

ANTIDOTE OVER DOSAGE a. PRENALTEROL: SELECTIVE 1 AGONIST, MAY BE USED IN -BLOCKERS’ TOXICITY CAUSED BY HIGH DOSES. b. Pressor agents c. Atropine d. Glucagon

CONTRA-INDICATIONS 1. ASTHMA 2. DIABETESE MELLITUS 3. HYPER LIPIDAEMIC STATES 4. DEPRESSION 5. PERIPHERAL VASCULAR DISEASES 6. 2ND OR 3RD DEGREE HEART BLOCK 7. HEART FAILURE INTERMITTENT CLAUDICATIONS

DRUG INTERACTIONS Enzyme inducers & Inhibitors Lignocaine & GAs Oral anti-diabetic drugs

Esmolol ultra short acting ester linkage Esterases in RBC rapidly metabolize esmolol. Useful supraventricular arrhythmias, arrhythmias associated with thyrotoxicosis, perioperative hypertension and myocardial ischemia.

Thank you